Scarica l'app Stockscreener
5.38
6.11%
-0.35
Precedente Chiudi:
$5.73
Aprire:
$5.72
Volume 24 ore:
257.81K
Relative Volume:
1.04
Capitalizzazione di mercato:
$117.74M
Reddito:
-
Utile/perdita netta:
$-69.87M
Rapporto P/E:
-1.6766
EPS:
-3.2089
Flusso di cassa netto:
$-61.75M
1 W Prestazione:
-7.08%
1M Prestazione:
-25.59%
6M Prestazione:
-4.61%
1 anno Prestazione:
-36.63%
Intervallo 1D:
$5.15
$5.991
Intervallo di 1 settimana:
$5.15
$6.245
Portata 52W:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Nome
Aardvark Therapeutics Inc
Settore
Industria
Telefono
(858) 225-7696
Indirizzo
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
5.38 | 128.90M | 0 | -69.87M | -61.75M | -3.2089 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | Downgrade | Stifel | Buy → Hold |
| 2026-01-28 | Iniziato | B. Riley Securities | Buy |
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-12 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Raymond James | Strong Buy |
| 2025-11-07 | Iniziato | BTIG Research | Buy |
| 2025-09-29 | Iniziato | Stifel | Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Iniziato | BofA Securities | Buy |
| 2025-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Iniziato | Morgan Stanley | Overweight |
| 2025-03-10 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DEADLINE ALERT for HDB, SMPL, and AARD: The Law Offices of - GlobeNewswire
Aardvark Therapeutics, Inc. (AARD) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 13, 2026 - ACCESS Newswire
2026-08-21 | Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (NASDAQ: AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action | NDAQ:AARD | Press Release - Stockhouse
Aardvark Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsAARD - WBOC TV
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Sahm
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops - TipRanks
LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation - Morningstar
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits
AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities LawsuitContact SueWallSt - Morningstar
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026AARD - Business Wire
Aardvark Therapeutics Faces Securities Class Action Lawsuit - Intellectia AI
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and DirectorsAARD - PR Newswire
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT - GlobeNewswire
Aardvark (AARD) Quarterly Figures: EPS Falls Short of Its Estimate in the Current Update; Share Move: The Stock Records a 9.85% Increase in the Latest SessionEarnings Power Value - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Lost Money on Aardvark Therapeutics, Inc. (AARD)? Urged to Join Class Action Before October 13, 2026Contact Levi & Korsinsky - ACCESS Newswire
Lawsuit ALERT: Investors who lost money with shares of Aardvark Therapeutics, Inc. (NASDAQ: AARD) - openPR.com
AARD Class Action ReminderRobbins LLP Reminds Investors - GlobeNewswire
Securities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit - TMX Newsfile
AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class ActionContact Levi & Korsinsky - PR Newswire
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Aardvark - GlobeNewswire
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aardvark (AARD) Results at a Glance: The Bottom-Line Figure Trails Its Comparison at the Close; Market Read: The Stock Records a 9.27% Decrease in the Latest SessionGuidance vs Actual - vinanet.vn
Bronstein, Gewirtz & Grossman LLC Urges Aardvark - GlobeNewswire
Kaplan Fox Encourages Investors of Aardvark Therapeutics, Inc. (N - The National Law Review
Shareholders sue Aardvark Therapeutics over all... - Pluang
AARDVARK THERAPEUTICS, INC. (AARD) INVESTOR ALERT Investors With Large Losses in Aardvark Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - TMX Newsfile
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Class Action - PR Newswire
AARD Investor Notice: Hagens Berman Alerts Investors in - GlobeNewswire
Aardvark Therapeutics Shareholders Approve Governance and Incentives - TipRanks
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
AARD Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aardvark Therapeutics, Inc. - Business Wire
Class action filed against Aardvark Therapeutics over safety issues and FDA clinical hold on drug trial. - Pluang
Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
AARD INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire
Aardvark Therapeutics held annual shareholder meeting - Bitget
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark ( - GuruFocus
AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 - Business Wire
Analysts Offer Insights on NA Companies: Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD) - The Globe and Mail
BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating - Moomoo
Aardvark Therapeutics (NASDAQ:AARD) Raised to "Sell" at Wall Street Zen - MarketBeat
Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action - lincolnjournal.com
Aardvark Therapeutics, Inc. Common Stock (NASDAQ: AARD) Stock Price, News & Analysis - Kalkine
Aardvark Therapeutics Company Profile & Introduction - Moomoo
Aardvark Therapeutics (AARD) Retreats 2.4%: Stock Holds Above Key $6.09 SupportTriple Top - Vinanet
Aardvark Therapeutics (AARD) Slips 2.13% to $6.43 as Traders Eye Key Support at $6.11Total Put Call - vinanet.vn
Aardvark Therapeutics Inc Azioni (AARD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aardvark Therapeutics Inc Azioni (AARD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):